Heron Therapeutics, Inc. (NASDAQ:HRTX) Given Average Rating of “Hold” by Brokerages

Heron Therapeutics, Inc. (NASDAQ:HRTX) has been given a consensus recommendation of “Hold” by the five research firms that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $4.50.

A number of analysts have weighed in on HRTX shares. HC Wainwright restated a “buy” rating and set a $6.00 price objective on shares of Heron Therapeutics in a research note on Friday, January 9th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Heron Therapeutics in a report on Thursday, January 22nd. Finally, Jefferies Financial Group restated a “buy” rating on shares of Heron Therapeutics in a report on Tuesday, November 4th.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. ProShare Advisors LLC boosted its position in Heron Therapeutics by 23.4% in the second quarter. ProShare Advisors LLC now owns 31,368 shares of the biotechnology company’s stock worth $65,000 after purchasing an additional 5,953 shares during the last quarter. SG Americas Securities LLC lifted its stake in shares of Heron Therapeutics by 39.1% in the 4th quarter. SG Americas Securities LLC now owns 24,377 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 6,858 shares during the period. Richmond Brothers Inc. boosted its holdings in shares of Heron Therapeutics by 1.8% in the second quarter. Richmond Brothers Inc. now owns 554,469 shares of the biotechnology company’s stock worth $1,148,000 after buying an additional 9,568 shares during the last quarter. The Manufacturers Life Insurance Company grew its position in Heron Therapeutics by 5.1% during the second quarter. The Manufacturers Life Insurance Company now owns 241,048 shares of the biotechnology company’s stock valued at $499,000 after buying an additional 11,716 shares during the period. Finally, B. Riley Wealth Advisors Inc. bought a new stake in Heron Therapeutics during the second quarter valued at approximately $26,000. Hedge funds and other institutional investors own 80.01% of the company’s stock.

Heron Therapeutics Price Performance

HRTX opened at $1.17 on Thursday. The firm has a market cap of $214.53 million, a PE ratio of -13.00 and a beta of 1.25. The stock has a 50-day moving average price of $1.34 and a 200-day moving average price of $1.31. Heron Therapeutics has a 1 year low of $1.00 and a 1 year high of $2.68. The company has a debt-to-equity ratio of 19.89, a current ratio of 2.56 and a quick ratio of 1.78.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and commercializing therapies in pain management and supportive care for patients undergoing medical and surgical procedures. The company’s research is dedicated to addressing unmet needs in oncology supportive care and post-operative pain management through innovative drug formulations designed to improve patient outcomes and reduce reliance on opioids.

Heron’s first approved therapy, SUSTOL (granisetron) extended-release injection, received U.S.